• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

通过全因子设计优化使用泊洛沙姆 407 和 HPMC 的化学稳定性氯霉素原位凝胶制剂。

Optimizing chemically stable chloramphenicol in-situ gel formulations using poloxamer 407 and HPMC through full-factorial design.

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.

Faculty of Medicine, Universitas Padjadjaran, Sumedang, West Java, Indonesia.

出版信息

Sci Rep. 2024 Oct 25;14(1):25344. doi: 10.1038/s41598-024-74945-w.

DOI:10.1038/s41598-024-74945-w
PMID:39455653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512008/
Abstract

The primary goal was to enhance the stability and bioavailability of chloramphenicol for ophthalmic use without compromising patient comfort, such as causing blurry vision. This study employed a 2-level full factorial design to optimize the formulation, exploring different concentrations of poloxamer 407 and HPMC to achieve this objective.

摘要

主要目标是提高氯霉素滴眼剂的稳定性和生物利用度，同时又不影响患者的舒适度，如引起视力模糊。本研究采用 2 水平完全析因设计来优化配方，探索不同浓度的泊洛沙姆 407 和 HPMC 以实现这一目标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/89e3ab0b8909/41598_2024_74945_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/1cdee9d342ea/41598_2024_74945_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/62e12b3e24bc/41598_2024_74945_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/402b0a0bf459/41598_2024_74945_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/89bc98756cc3/41598_2024_74945_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/f4d75278dc27/41598_2024_74945_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/c14c9ba5bb96/41598_2024_74945_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/109dae14d270/41598_2024_74945_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/5a7dac43e677/41598_2024_74945_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/d6c44fecf0ed/41598_2024_74945_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/77020e90d528/41598_2024_74945_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/5fe64ab55ccf/41598_2024_74945_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/e1a12c79a855/41598_2024_74945_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/89e3ab0b8909/41598_2024_74945_Fig13_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/1cdee9d342ea/41598_2024_74945_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/62e12b3e24bc/41598_2024_74945_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/402b0a0bf459/41598_2024_74945_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/89bc98756cc3/41598_2024_74945_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/f4d75278dc27/41598_2024_74945_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/c14c9ba5bb96/41598_2024_74945_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/109dae14d270/41598_2024_74945_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/5a7dac43e677/41598_2024_74945_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/d6c44fecf0ed/41598_2024_74945_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/77020e90d528/41598_2024_74945_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/5fe64ab55ccf/41598_2024_74945_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/e1a12c79a855/41598_2024_74945_Fig12_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4624/11512008/89e3ab0b8909/41598_2024_74945_Fig13_HTML.jpg

相似文献

1
Optimizing chemically stable chloramphenicol in-situ gel formulations using poloxamer 407 and HPMC through full-factorial design.通过全因子设计优化使用泊洛沙姆 407 和 HPMC 的化学稳定性氯霉素原位凝胶制剂。
Sci Rep. 2024 Oct 25;14(1):25344. doi: 10.1038/s41598-024-74945-w.
2
Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.运用质量源于设计理念研制用于治疗眼部炎症和感染的眼用原位凝胶剂。
Drug Dev Ind Pharm. 2016 Sep;42(9):1406-23. doi: 10.3109/03639045.2015.1137306. Epub 2016 Jan 29.
3
Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: formulation, optimization, evaluation and permeation studies.基于泊洛沙姆407的载佐米曲普坦纳米脂质体鼻腔内温度可逆凝胶：制剂、优化、评价及渗透研究
J Liposome Res. 2016 Dec;26(4):313-23. doi: 10.3109/08982104.2015.1132232. Epub 2016 Jan 12.
4
Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and in vitro/in vivo evaluation.用于克霉唑阴道给药的黏膜黏附原位凝胶制剂：制剂、制备及体外/体内评价
Pharm Dev Technol. 2017 Jun;22(4):551-561. doi: 10.3109/10837450.2016.1163385. Epub 2016 Apr 7.
5
Development of poloxamer gel formulations via hot-melt extrusion technology.通过热熔挤出技术开发泊洛沙姆凝胶制剂。
Int J Pharm. 2018 Feb 15;537(1-2):122-131. doi: 10.1016/j.ijpharm.2017.12.008. Epub 2017 Dec 16.
6
Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels.基于泊洛沙姆的眼用盐酸环丙沙星原位凝胶
Drug Dev Ind Pharm. 2008 Jul;34(7):744-52. doi: 10.1080/03639040801926030.
7
Formulation, Optimization and In-Vivo Characterization of Thermosensitive In-Situ Nasal Gel Loaded with Bacoside a for Treatment of Epilepsy.载有 Bacoside a 的温敏型原位鼻腔凝胶的配方优化及体内特征研究，用于癫痫治疗。
AAPS PharmSciTech. 2024 Jul 1;25(6):151. doi: 10.1208/s12249-024-02870-2.
8
[Real-time UV imaging of chloramphenicol intrinsic dissolution characteristics from ophthalmic in situ gel].[氯霉素眼用原位凝胶固有溶出特性的实时紫外成像]
Yao Xue Xue Bao. 2013 Jul;48(7):1156-63.
9
Dissolution and bioavailability of lercanidipine-hydroxypropylmethyl cellulose nanoparticles with surfactant.含表面活性剂的乐卡地平-羟丙基甲基纤维素纳米粒的溶出度与生物利用度
Int J Biol Macromol. 2015 Jan;72:218-22. doi: 10.1016/j.ijbiomac.2014.08.017. Epub 2014 Aug 23.
10
Design and formulation of mebeverine HCl semisolid formulations for intraorally administration.盐酸美贝维林半固体制剂的设计和配方，用于口腔内给药。
AAPS PharmSciTech. 2010 Mar;11(1):181-8. doi: 10.1208/s12249-009-9374-3. Epub 2010 Jan 26.

引用本文的文献

1
Development of an Ophthalmic Hydrogel to Deliver MG53 and Promote Corneal Wound Healing.一种用于递送MG53并促进角膜伤口愈合的眼科水凝胶的研发。
Pharmaceutics. 2025 Apr 16;17(4):526. doi: 10.3390/pharmaceutics17040526.

本文引用的文献

1
Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery.用于眼部给药的离子敏感型酒石酸溴莫尼定原位凝胶的制备与表征
Pharmaceuticals (Basel). 2023 Jan 8;16(1):90. doi: 10.3390/ph16010090.
2
Poloxamer sols endowed with in-situ gelability and mucoadhesion by adding hypromellose and hyaluronan for prolonging corneal retention and drug delivery.通过添加羟丙甲纤维素和透明质酸赋予泊洛沙姆溶胶原位凝胶形成能力和黏膜黏附性，以延长角膜滞留时间和药物传递。
Drug Deliv. 2023 Dec;30(1):2158964. doi: 10.1080/10717544.2022.2158964.
3
Balance of Drug Residence and Diffusion in Lacrimal Fluid Determine Ocular Bioavailability in In Situ Gels Incorporating Tranilast Nanoparticles.
泪液中药物滞留与扩散的平衡决定了含曲尼司特纳米颗粒的原位凝胶的眼部生物利用度。
Pharmaceutics. 2021 Sep 8;13(9):1425. doi: 10.3390/pharmaceutics13091425.
4
Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.滴眼剂剂型提高眼部生物利用度的方法综述。
AAPS PharmSciTech. 2021 Mar 14;22(3):107. doi: 10.1208/s12249-021-01977-0.
5
ophthalmic gel forming systems of poloxamer 407 and hydroxypropyl methyl cellulose mixtures for sustained ocular delivery of chloramphenicole: optimization study by factorial design.泊洛沙姆407与羟丙基甲基纤维素混合物的眼用凝胶形成系统用于氯霉素的眼部持续给药：析因设计优化研究
Heliyon. 2020 Nov 13;6(11):e05365. doi: 10.1016/j.heliyon.2020.e05365. eCollection 2020 Nov.
6
Physical study of Chloramphenicol Gel with Base Hydroxypropyl Methylcellulose and Poloxamer 188.含辅料羟丙基甲基纤维素和泊洛沙姆188的氯霉素凝胶的物理研究
J Pharm Bioallied Sci. 2019 Dec;11(Suppl 4):S547-S550. doi: 10.4103/jpbs.JPBS_201_19. Epub 2019 Dec 30.
7
Research progress of in-situ gelling ophthalmic drug delivery system.原位凝胶眼部给药系统的研究进展
Asian J Pharm Sci. 2019 Jan;14(1):1-15. doi: 10.1016/j.ajps.2018.04.008. Epub 2018 May 24.
8
Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications.泊洛沙姆基原位凝胶温敏递药系统及其在眼部给药中的应用。
Drug Discov Today. 2019 Aug;24(8):1575-1586. doi: 10.1016/j.drudis.2019.05.036. Epub 2019 Jun 5.
9
Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview.泊洛沙姆407基水凝胶的黏膜应用：综述
Pharmaceutics. 2018 Sep 12;10(3):159. doi: 10.3390/pharmaceutics10030159.
10
Design of experiments (DoE) in pharmaceutical development.药物研发中的实验设计
Drug Dev Ind Pharm. 2017 Jun;43(6):889-901. doi: 10.1080/03639045.2017.1291672. Epub 2017 Feb 23.